We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+29.79%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$474M
AUM Growth
+$47.9M
Cap. Flow
-$48.4M
Cap. Flow %
-10.21%
Top 10 Hldgs %
33.88%
Holding
142
New
32
Increased
21
Reduced
37
Closed
28

Top Buys

Rank Stock Value
1
NICE icon
Nice
NICE
+$23.6M
2
QQQ icon
Invesco QQQ Trust
QQQ
+$13.1M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$7.57M
4
CLBT icon
Cellebrite
CLBT
+$4.7M
5
VRNS icon
Varonis Systems
VRNS
+$4.1M

Top Sells

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$15.5M
2
NVMI
Nova
NVMI
+$8.82M
3
NVDA icon
NVIDIA
NVDA
+$8.61M
4
CYTK icon
Cytokinetics
CYTK
+$6.81M
5
TVTX icon
Travere Therapeutics
TVTX
+$6.3M

Sector Composition

Rank Sector Weight
1 Healthcare 64.08%
2 Technology 17.97%
3 Industrials 0.72%
4 Consumer Discretionary 0.64%
5 Communication Services 0.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMZN icon
51
Amazon
AMZN
$2.53T
$3.02M 0.64%
13,760
-18,681
-58% -$4.23M
CRVS icon
52
Corvus Pharmaceuticals
CRVS
$1.11B
$3M 0.63%
407,709
+224,615
+123% +$1.15M
PHVS icon
53
Pharvaris
PHVS
$2.37B
$2.98M 0.63%
119,406
-190,525
-61% -$4.23M
SRPT icon
54
CALL
Sarepta Therapeutics
SRPT
$1.64B
$2.89M 0.61%
150,000
– –
META icon
55
Meta Platforms (Facebook)
META
$1.37T
$2.88M 0.61%
3,924
-4,602
-54% -$3.43M
SLNO
56
DELISTED
Soleno Therapeutics
SLNO
$2.81M 0.59%
+41,606
New +$3.08M
RVMD icon
57
Revolution Medicines
RVMD
$40.9B
$2.8M 0.59%
+60,000
New +$2.35M
ORA icon
58
Ormat Technologies
ORA
$5.94B
$2.79M 0.59%
29,000
-49,000
-63% -$4.42M
IDYA icon
59
IDEAYA Biosciences
IDYA
$3.5B
$2.72M 0.57%
+100,000
New +$2.42M
AMGN icon
60
Amgen
AMGN
$209B
$2.68M 0.57%
9,500
– –
PRAX icon
61
CALL
Praxis Precision Medicines
PRAX
$8.58B
$2.65M 0.56%
50,000
-50,000
-50% -$2.42M
AMD icon
62
Advanced Micro Devices
AMD
$791B
$2.5M 0.53%
15,470
+7,220
+88% +$1.17M
TVTX icon
63
CALL
Travere Therapeutics
TVTX
$5.33B
$2.43M 0.51%
+101,800
New +$1.91M
ROIV icon
64
CALL
Roivant Sciences
ROIV
$24.9B
$2.29M 0.48%
+151,600
New +$1.88M
ACOG
65
Alpha Cognition
ACOG
$190M
$2.21M 0.47%
338,752
-37,897
-10% -$345K
PFE icon
66
Pfizer
PFE
$142B
$2.19M 0.46%
86,000
– –
HELP
67
Cybin Inc
HELP
$505M
$2.18M 0.46%
370,376
-27,933
-7% -$198K
KURA icon
68
Kura Oncology
KURA
$826M
$2.17M 0.46%
245,522
+10,000
+4% +$71.3K
AVGO icon
69
Broadcom
AVGO
$1.85T
$2.16M 0.46%
+6,555
New +$2.01M
CEVA icon
70
CEVA Inc
CEVA
$916M
$2.14M 0.45%
81,085
+32,165
+66% +$749K
BBIO icon
71
BridgeBio Pharma
BBIO
$16.1B
$2.12M 0.45%
40,746
-46,362
-53% -$2.26M
JANX icon
72
Janux Therapeutics
JANX
$950M
$2.1M 0.44%
85,840
– –
SKYE icon
73
Skye Bioscience
SKYE
$20.4M
$1.88M 0.4%
478,928
-59,506
-11% -$225K
ATXS
74
DELISTED
Astria Therapeutics
ATXS
$1.83M 0.39%
251,225
-6,177
-2% -$41.8K
TECX
75
Tectonic Therapeutic
TECX
$538M
$1.82M 0.38%
+115,908
New +$2.39M
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
PA
Probity Advisors Dallas, Texas $631M AUM 17.4% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return

Sphera Funds Management's Q3 2025 Portfolio in Review

As of Q3 2025, Sphera Funds Management held 142 positions worth $474M, up 11% from $426M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Sphera Funds Management withdrew a net $48.4M in Q3 2025, closing 28 positions and reducing 37 holdings. Its most notable exit was NVIDIA, an estimated $8.61M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 66% a quarter earlier, followed by Technology and Industrials.

Against the trend, Sphera Funds Management opened a new position in Nice worth $22.8M.

  • Sphera Funds Management's largest Q3 2025 buy was Nice: 157,400 shares worth $22.8M.
  • Sphera Funds Management added most to Ultragenyx Pharmaceutical in Q3 2025, an estimated $7.57M increase.
  • Sphera Funds Management's biggest Q3 2025 reduction was Syndax Pharmaceuticals, cutting an estimated $15.5M.
  • Sphera Funds Management fully exited NVIDIA in Q3 2025, selling an estimated $8.61M.
  • Sphera Funds Management's ten largest holdings make up 34% of its $474M portfolio in Q3 2025.
  • Sphera Funds Management opened 32 new positions and closed 28 in Q3 2025.
  • Sphera Funds Management's portfolio value rose 11% quarter-over-quarter to $474M.

Based on Sphera Funds Management's 13F filing for Q3 2025, filed 14 Nov 2025.